Studies on Sepsis and severe infections
14
October, 2026
Innate immune response in COVID-19 pneumonia during the pandemic: a prospective cohort study
Annals of Intensive Care, Volume 16, 2026
15
September, 2026
CLASSIFY
Ongoing study Official Study Title CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS Brief Description The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized
14
December, 2025
9
April, 2025
The EMBRACE trial at the 44th International Symposium of Intensive Care and Emergency Medicine
Ourania Konstantinidou, Elisavet Olntasi, Helena Florou, Souzana Anisoglou, Eleni Antoniadou, George Dimopoulos, Eleni Gkeka, Aikaterini Ioakeimidou, Vassileios Karamouzos, Efmorphia Kondili, Zafeiria Mastora, Eleni Mouloudi, Pavlos Myrianthefs, Maria Ntaganou, Elissavet Paramythiotou, Vassilis Papaioannou, Maria Patrani, Nikoletta Rovina, Glykeria Vlachogianni, Armin J. Reininger, Evangelos J. Giamarellos-Bourboulis 44th International Symposium of Intensive Care and Emergency
12
March, 2025
EMBRACE
Completed studyOfficial Study TitleEMapalumaB treatment foR Anticipated Clinical benefit in sepsis driven by the Interferon-Gamma Endotype (The EMBRACE trial)Brief DescriptionIn a recent analysis of 5,503 patients with sepsis meeting the Sepsis-3 definitions and coming from Germany, Greece and Italy randomized into one discovery set and one validation set, it was found that one endotype driven
27
December, 2024
POINT study
Personalised care for post-COVID-19 health Connect to the official POINT website Ongoing study Official Study Title A non-interventional, Prospective, cross-sectional study Of the INcidence of pulmonary, cardiovascular and renal system non-communicable complications associated with the post-acute phase of the infecTion by SARS-CoV-2 Brief Description POINT is an innovative research project funded
29
November, 2024
HOMI-LUNG CAP
A STRONG CONSORTIUM TO FILL THE GAP Pneumonia is a heart matter too (and viceversa) Connect to the official HOMI-LUNG CAP website Ongoing study Official Study Title A non-interventional, prospective, cross-sectional study of cardiovascular disease progression in survivors of community acquired pneumonia and lung infection by SARS-CoV-2 Brief Description HOMI-LUNG is
13
February, 2024
REACT
Completed study Official Study Title BiomarkeR-guided EArly Clarithromycin Treatment to prevent sepsis progression in community-acquired pneumonia: The REACT Randomized clinical trial Brief Description The primary objective of the REACT RCT is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of
1
September, 2023
PRECISION
HISS: Facing the LONG-COVID syndrome Ongoing study Official Study Title Safety and efficacy of Anakinra treatment for patients with Persistent REspiratory symptoms post-acute COVID and Immune System activatION: the PRECISION double-blind, randomized clinical trial Brief Description The effect of the drug anakinra in the treatment of long-term complications after COVID-19. The
15
February, 2023
MODIFY
Ongoing study Official Study Title A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial) Brief Description The aim of the study is to demonstrate if using a combined strategy of rapid molecular diagnosis with BioFire® FilmArray® Blood Culture Identification 2 Panel and